BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 31748823)

  • 21. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectability.
    Jang JK; Choi SJ; Byun JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Hwang DW; Kim SC
    J Hepatobiliary Pancreat Sci; 2022 Sep; 29(9):1025-1034. PubMed ID: 35658103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system.
    Rochefort MM; Ankeny JS; Kadera BE; Donald GW; Isacoff W; Wainberg ZA; Hines OJ; Donahue TR; Reber HA; Tomlinson JS
    Ann Surg Oncol; 2013 Dec; 20(13):4322-9. PubMed ID: 23943022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ACR Appropriateness Criteria
    ; Qayyum A; Tamm EP; Kamel IR; Allen PJ; Arif-Tiwari H; Chernyak V; Gonda TA; Grajo JR; Hindman NM; Horowitz JM; Kaur H; McNamara MM; Noto RB; Srivastava PK; Lalani T
    J Am Coll Radiol; 2017 Nov; 14(11S):S560-S569. PubMed ID: 29101993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synoptic CT scan reporting of pancreatic adenocarcinoma to align with international consensus guidelines on surgical resectability: a Victorian pilot.
    Pilgrim CHC; Maciejewska A; Ayres N; Ellis S; Goodwin M; Zalcberg JR; Haydon A
    ANZ J Surg; 2022 Oct; 92(10):2565-2570. PubMed ID: 36054233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
    Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
    Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A patient-centered, multidisciplinary approach to treating borderline resectable pancreatic adenocarcinoma.
    Hester CA; Katz MHG
    Chin Clin Oncol; 2022 Dec; 11(6):45. PubMed ID: 36509553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association.
    Al-Hawary MM; Francis IR; Chari ST; Fishman EK; Hough DM; Lu DS; Macari M; Megibow AJ; Miller FH; Mortele KJ; Merchant NB; Minter RM; Tamm EP; Sahani DV; Simeone DM
    Radiology; 2014 Jan; 270(1):248-60. PubMed ID: 24354378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer.
    Kato Y; Yamada S; Tashiro M; Sonohara F; Takami H; Hayashi M; Kanda M; Kobayashi D; Tanaka C; Nakayama G; Koike M; Fujiwara M; Kodera Y
    HPB (Oxford); 2019 Sep; 21(9):1211-1218. PubMed ID: 30773450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mesenterico-portal vein invasion should be an important factor in TNM staging for pancreatic ductal adenocarcinoma: Proposed modification of the 8
    Chen HY; Wang X; Zhang H; Liu XB; Tan CL
    World J Gastroenterol; 2019 Dec; 25(46):6752-6766. PubMed ID: 31857777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma.
    Rowan DJ; Hartley CP; Aldakkak M; Christians KK; Evans DB; Tsai S; Hagen CE
    Ann Diagn Pathol; 2020 Jun; 46():151485. PubMed ID: 32172219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer.
    Lombardi P; Silvestri S; Marino D; Santarelli M; Campra D; De Paolis P; Aglietta M; Leone F;
    Crit Rev Oncol Hematol; 2019 Jan; 133():17-24. PubMed ID: 30661653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Artificial intelligence for assessment of vascular involvement and tumor resectability on CT in patients with pancreatic cancer.
    Bereska JI; Janssen BV; Nio CY; Kop MPM; Kazemier G; Busch OR; Struik F; Marquering HA; Stoker J; Besselink MG; Verpalen IM;
    Eur Radiol Exp; 2024 Feb; 8(1):18. PubMed ID: 38342782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Changes in the American Joint Committee on Cancer Staging Manual, Eighth Edition, for Pancreatic Ductal Adenocarcinoma.
    Kassardjian A; Stanzione N; Donahue TR; Wainberg ZA; Damato L; Wang HL
    Pancreas; 2019 Aug; 48(7):876-882. PubMed ID: 31268985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Borderline resectable pancreatic cancer.
    Hackert T; Ulrich A; Büchler MW
    Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma.
    Sakaguchi T; Satoi S; Yamamoto T; Yamaki S; Sekimoto M
    Surg Today; 2020 Apr; 50(4):335-343. PubMed ID: 31993761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma.
    Shin DW; Lee JC; Kim J; Woo SM; Lee WJ; Han SS; Park SJ; Choi KS; Cha HS; Yoon YS; Han HS; Hong EK; Hwang JH
    Eur J Surg Oncol; 2019 Nov; 45(11):2159-2165. PubMed ID: 31202572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification.
    Gilbert JW; Wolpin B; Clancy T; Wang J; Mamon H; Shinagare AB; Jagannathan J; Rosenthal M
    Ann Oncol; 2017 Sep; 28(9):2067-2076. PubMed ID: 28407088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer.
    van Roessel S; Kasumova GG; Verheij J; Najarian RM; Maggino L; de Pastena M; Malleo G; Marchegiani G; Salvia R; Ng SC; de Geus SW; Lof S; Giovinazzo F; van Dam JL; Kent TS; Busch OR; van Eijck CH; Koerkamp BG; Abu Hilal M; Bassi C; Tseng JF; Besselink MG
    JAMA Surg; 2018 Dec; 153(12):e183617. PubMed ID: 30285076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AJCC 7th edition staging classification is more applicable than AJCC 8th edition staging classification for invasive IPMN.
    Fan Z; Cheng H; Jin K; Gong Y; Huang Q; Xu J; Ni Q; Yu X; Liu C; Luo G
    World J Surg Oncol; 2019 Aug; 17(1):137. PubMed ID: 31387646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.